JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$5.47B |
| 2 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$3.17B |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$2.05B |
| 4 |
Amazon
AMZN
|
+$1.96B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.6B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$1.72B |
| 2 |
Vanguard Intermediate-Term Treasury ETF
VGIT
|
+$1.31B |
| 3 |
UnitedHealth
UNH
|
+$1.26B |
| 4 |
Automatic Data Processing
ADP
|
+$1.17B |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$1.08B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 27.28% |
| 2 | Technology | 17.17% |
| 3 | Healthcare | 10.79% |
| 4 | Financials | 9.36% |
| 5 | Consumer Discretionary | 8.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4226
UroGen Pharma
URGN
$2.03B
| $558K | ﹤0.01% |
60,391
+59,695
| +8,577% | +$549K |
2019 Q2
15 quarters
|
|
|
SFIX
4227
Stitch Fix
SFIX
$357M
| $557K | ﹤0.01% |
108,948
+58,821
| +117% | +$276K |
2018 Q2
19 quarters
|
|
|
WBA
4228
CALL
DELISTED
Walgreens Boots Alliance
WBA
| $557K | ﹤0.01% |
16,100
-190,200
| -92% | -$6.75M |
2020 Q3
10 quarters
|
|
4229
Direxion Daily GOOGL Bull 2X ETF
GGLL
$1.1B
| $554K | ﹤0.01% |
25,000
| – | – |
2022 Q3
2 quarters
|
|
4230
ProShares UltraShort S&P500
SDS
$356M
| $553K | ﹤0.01% |
+2,768
| New | +$587K |
2023 Q1
0 quarters
|
|
4231
Greif Class B
GEF.B
$4.08B
| $552K | ﹤0.01% |
7,213
-145
| -2% | -$11.3K |
2017 Q4
21 quarters
|
|
4232
FT Vest US Equity Deep Buffer ETF April
DAPR
$327M
| $551K | ﹤0.01% |
18,579
+18,278
| +6,072% | +$542K |
2022 Q4
1 quarter
|
|
4233
Ivanhoe Electric
IE
$1.66B
| $549K | ﹤0.01% |
45,159
+30,459
| +207% | +$408K |
2022 Q2
3 quarters
|
|
|
PR
4234
CALL
Permian Resources
PR
$18.7B
| $549K | ﹤0.01% |
+52,300
| New | +$534K |
2023 Q1
0 quarters
|
|
|
EVV
4235
Eaton Vance Limited Duration Income Fund
EVV
$980M
| $547K | ﹤0.01% |
55,550
+48,550
| +694% | +$488K |
2022 Q4
1 quarter
|
|
4236
Taboola.com
TBLA
$873M
| $547K | ﹤0.01% |
201,004
+61,123
| +44% | +$206K |
2021 Q3
6 quarters
|
|
4237
Direxion Daily TSLA Bear 1X ETF
TSLS
$55.1M
| $547K | ﹤0.01% |
2,100
| – | – |
2022 Q3
2 quarters
|
|
|
GRFS
4238
PUT
Grifois
GRFS
$5.12B
| $546K | ﹤0.01% |
+74,100
| New | +$643K |
2023 Q1
0 quarters
|
|
4239
X4 Pharmaceuticals
XFOR
$275M
| $545K | ﹤0.01% |
20,868
+16,881
| +423% | +$495K |
2022 Q4
1 quarter
|
|
4240
Fulcrum Therapeutics
FULC
$282M
| $543K | ﹤0.01% |
190,269
+5,583
| +3% | +$50K |
2019 Q3
14 quarters
|
|
4241
ROBO Global Robotics & Automation Index ETF
ROBO
$2.1B
| $542K | ﹤0.01% |
9,918
+5,648
| +132% | +$295K |
2017 Q2
23 quarters
|
|
4242
CALL
Boston Properties
BXP
$9.55B
| $541K | ﹤0.01% |
10,000
-29,500
| -75% | -$1.92M |
2022 Q4
1 quarter
|
|
|
AMLI
4243
DELISTED
American Lithium Corp. Common Stock
AMLI
| $541K | ﹤0.01% |
+186,702
| New | +$548K |
2023 Q1
0 quarters
|
|
|
BGFV
4244
DELISTED
Big 5 Sporting Goods
BGFV
| $540K | ﹤0.01% |
70,292
+13,534
| +24% | +$122K |
2020 Q3
10 quarters
|
|
4245
Viemed Healthcare
VMD
$355M
| $540K | ﹤0.01% |
55,992
+55,841
| +36,981% | +$487K |
2020 Q2
11 quarters
|
|
|
ZINGU
4246
DELISTED
FTAC Zeus Acquisition Corp. Unit
ZINGU
| $540K | ﹤0.01% |
+52,666
| New | +$539K |
2023 Q1
0 quarters
|
|
4247
PUT
Carvana
CVNA
$46B
| $539K | ﹤0.01% |
275,500
-2,224,500
| -89% | -$3.86M |
2022 Q1
4 quarters
|
|
4248
Core Laboratories
CLB
$473M
| $538K | ﹤0.01% |
24,393
+2,898
| +13% | +$67.8K |
2013 Q2
39 quarters
|
|
4249
CALL
Cigna
CI
$72.5B
| $537K | ﹤0.01% |
2,100
-51,800
| -96% | -$15.1M |
2021 Q2
7 quarters
|
|
|
FCT
4250
DELISTED
First Trust Senior Floating Rate Income Fund II
FCT
| $537K | ﹤0.01% |
54,059
+39,370
| +268% | +$387K |
2022 Q4
1 quarter
|
|
Similar funds
JP Morgan Chase's Q1 2023 Portfolio in Review
As of Q1 2023, JP Morgan Chase held 7,579 positions worth $821B, up 8.2% from $759B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
JP Morgan Chase's Q1 2023 filing shows 751 new, 3,314 increased, 2,056 reduced and 652 closed positions. Its largest new stake was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M. The largest sale was Eli Lilly, an estimated $1.72B.
By sector, the portfolio is most concentrated in Miscellaneous at 27% of assets, up from 27% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q1 2023 buy was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M.
- JP Morgan Chase added most to JPMorgan BetaBuilders Europe ETF in Q1 2023, an estimated $5.47B increase.
- JP Morgan Chase's biggest Q1 2023 reduction was Eli Lilly, cutting an estimated $1.72B.
- JP Morgan Chase fully exited IAA, Inc. Common Stock in Q1 2023, selling an estimated $155M.
- JP Morgan Chase's ten largest holdings make up 17% of its $821B portfolio in Q1 2023.
- JP Morgan Chase opened 751 new positions and closed 652 in Q1 2023.
- JP Morgan Chase's portfolio value rose 8.2% quarter-over-quarter to $821B.
Based on JP Morgan Chase's 13F filing for Q1 2023, filed 11 May 2023.